INFORMACIÓN IMPORTANTE SELECCIONADA: No debe utilizar KOVALTRY® si es alérgico a los roedores (como ratones y hámsteres) o a cualquier ingrediente de KOVALTRY® SIGA LEYENDO A CONTINUACIÓN  >

Bayer is committed to helping you with insurance, financial or affordability challenges

Bayer is committed to helping you with insurance, financial or affordability challenges

Access Services by Bayer | KOVALTRY®, Antihemophilic Factor (Recombinant)

Take advantage of all that Access Services by Bayer can offer, including:

Patient Loyalty Program hands interlocked graphic.

Patient Loyalty Program†§

Bayer is committed to helping you start and stay on therapy regardless of changes in your commercial health insurance coverage status.

Eligible patients can receive KOVALTRY® at no cost if you experience gaps or changes with insurance coverage.

Free Trial Program calendar graphic.

Free Trial Program‡§

Patients new to KOVALTRY can receive 1 month of free therapy.

  • The selected product is delivered to your home.
  • Any patient new to KOVALTRY is able to participate, regardless of insurance type or status.
Zero dollar co-pay program phone operator graphic.

$0 Co-Pay Program*†

  • Most commercially insured patients can receive KOVALTRY for as little as $0 per prescription, regardless of income. (up to $20,000 in out-of-pocket cost assistance available per year.)
  • Assistance is awarded per patient. Multiple members of the same household can apply.

Click here or call 1-800-288-8374 to get started saving today!

Free trial program lab vial graphic.

Reimbursement
for Lab Testing*†

You may be able to receive up to $250 per year to offset out-of-pocket costs for laboratory tests for KOVALTRY.

Download and submit this form to process your reimbursement claim for KOVALTRY.

Access services by Bayer logo.

this checklist and complete the next steps of enrollment with your physician.

Speak with a health insurance expert. Live helpline support from 9:00 AM - 6:00 PM ET, Monday-Friday. Multiple languages, including Spanish, are available.

*Co-pay program support is available for up to 1 year. Can include any out-of-pocket prescription costs, such as co-pay and co-insurance. Up to $20,000 in co-pay assistance available per year. Eligible patients will be auto-enrolled every January.
†Patients who are enrolled in any type of government insurance are not eligible. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.
‡Participation in the KOVALTRY Free Trial Program is limited to 1 time only per product (patients currently using KOVALTRY are not eligible for a Free Trial of their current product). The Free Trial Program includes 1 month supply up to a maximum of 40,000 IU. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.
§The medication provided through this program is at no cost to the patient and is not contingent on future use of this medication. Reselling or billing any third party for free product provided by this program is prohibited by law.
¶Formulary status is believed to be accurate as of January 1, 2022 but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level. Lower co-pay costs do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status does not imply a comparison of efficacy, safety, or dosing. 
#KOVALTRY coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), Managed Medicaid (100%) & Medicare Advantage (100%). Percentage represents the plan coverage within the book of business: n=1,798; 51; 410; 1,112.

INDICATION FOR KOVALTRY®

KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.

KOVALTRY is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY when you have surgery.

KOVALTRY is not used to treat von Willebrand Disease.

IMPORTANT SAFETY INFORMATION

You should not use KOVALTRY if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY.

Tell your healthcare provider if you have heart disease or are at risk for heart disease.

The common side effects of KOVALTRY are fever, headache, and rash, in addition to inhibitors in patients who were not previously treated or minimally treated with Factor VIII products.

Your body may make antibodies, called “inhibitors” against KOVALTRY, which may stop KOVALTRY from working properly. If your bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.

Allergic reactions may occur with KOVALTRY. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.

Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY.

For additional important risk and use information, please see full Prescribing Information.